SutroVax, a South San Francisco, CA-based biopharmaceutical vaccine company, completed a $22m Series A financing.
The round was led by Abingworth, the international investment group, with participation from Longitude Capital, Roche Venture Fund and CTI Life Sciences Fund. As part of the financing, Kurt von Emster, Managing Partner of Abingworth, will become interim Chairman at SutroVax. In addition, Patrick Enright and Dr. Tracy Saxtonfrom Longitude Capital and Roche Venture Fund, respectively, will join the board of directors.
The company intends to use the funds to advance multiple vaccines in its pipeline through pre-clinical proof of concept.
Led by Grant Pickering, CEO, SutroVax is developing vaccines for infectious disease targets, with an initial emphasis on conjugate vaccines, using an exclusive license to Sutro Biopharma’s Xpress CF™ and Xpress CF+™ platforms for cell free protein synthesis and site-specific conjugation respectively.